Lonitoclax

Lonitoclax is an investigational new drug that is being evaluated by Lomond Therapeutics for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukaemia (CML).

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Lonitoclax is an investigational new drug that is being evaluated by Lomond Therapeutics for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukaemia (CML). It acts as an Bcl-2 inhibitor.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1365630611 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.